Company intelligence / Profile preview
Innogen Pharmaceutical Technology Co., Ltd.
Shanghai, Chinainnogen-pharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Innogen has a deep pipeline focused on metabolic diseases such as type 1 and type 2 diabetes, obesity, and NASH. Their lead program is a first-in-class GLP‑1 receptor agonist called Diabegone for type 2 diabetes. The company holds global market rights to its independently developed pipeline. Detailed clinical results are not publicly available.
- Therapeutic areas
- GastroenterologyEndocrinology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Innogen Pharmaceutical Technology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Innogen Pharmaceutical Technology Co., Ltd..